Daniel P Barboriak
Overview
Explore the profile of Daniel P Barboriak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
2046
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kaufmann T, Smits M, Boxerman J, Huang R, Barboriak D, Weller M, et al.
Neuro Oncol
. 2020 Feb;
22(6):757-772.
PMID: 32048719
A recent meeting was held on March 22, 2019, among the FDA, clinical scientists, pharmaceutical and biotech companies, clinical trials cooperative groups, and patient advocacy groups to discuss challenges and...
12.
Barboriak D, Zhang Z, Desai P, Snyder B, Safriel Y, McKinstry R, et al.
Radiology
. 2018 Nov;
290(2):467-476.
PMID: 30480488
Purpose To evaluate factors contributing to interreader variation (IRV) in parameters measured at dynamic contrast material-enhanced (DCE) MRI in patients with glioblastoma who were participating in a multicenter trial. Materials...
13.
Boxerman J, Zhang Z, Safriel Y, Rogg J, Wolf R, Mohan S, et al.
Neuro Oncol
. 2018 Mar;
20(10):1400-1410.
PMID: 29590461
Background: ACRIN 6686/RTOG 0825 was a phase III trial of conventional chemoradiation plus adjuvant temozolomide with bevacizumab or without (placebo) in newly diagnosed glioblastoma. This study investigated whether changes in...
14.
Gerstner E, Zhang Z, Fink J, Muzi M, Hanna L, Greco E, et al.
Clin Cancer Res
. 2016 May;
22(20):5079-5086.
PMID: 27185374
Purpose: Structural and functional alterations in tumor vasculature are thought to contribute to tumor hypoxia which is a primary driver of malignancy through its negative impact on the efficacy of...
15.
Obuchowski N, Buckler A, Kinahan P, Chen-Mayer H, Petrick N, Barboriak D, et al.
Acad Radiol
. 2016 Feb;
23(4):496-506.
PMID: 26898527
A major initiative of the Quantitative Imaging Biomarker Alliance is to develop standards-based documents called "Profiles," which describe one or more technical performance claims for a given imaging modality. The...
16.
Boxerman J, Schmainda K, Zhang Z, Barboriak D
Neuro Oncol
. 2015 Sep;
17(11):1538-9.
PMID: 26361983
No abstract available.
17.
Sullivan D, Obuchowski N, Kessler L, Raunig D, Gatsonis C, Huang E, et al.
Radiology
. 2015 Aug;
277(3):813-25.
PMID: 26267831
Although investigators in the imaging community have been active in developing and evaluating quantitative imaging biomarkers (QIBs), the development and implementation of QIBs have been hampered by the inconsistent or...
18.
Lin N, Lee E, Aoyama H, Barani I, Barboriak D, Baumert B, et al.
Lancet Oncol
. 2015 Jun;
16(6):e270-8.
PMID: 26065612
CNS metastases are the most common cause of malignant brain tumours in adults. Historically, patients with brain metastases have been excluded from most clinical trials, but their inclusion is now...
19.
Ellingson B, Kim E, Woodworth D, Marques H, Boxerman J, Safriel Y, et al.
Int J Oncol
. 2015 Feb;
46(5):1883-92.
PMID: 25672376
Functional diffusion mapping (fDM) is a cancer imaging technique that quantifies voxelwise changes in apparent diffusion coefficient (ADC). Previous studies have shown value of fDMs in bevacizumab therapy for recurrent...
20.
Schmainda K, Zhang Z, Prah M, Snyder B, Gilbert M, Sorensen A, et al.
Neuro Oncol
. 2015 Feb;
17(8):1148-56.
PMID: 25646027
Background: The study goal was to determine whether changes in relative cerebral blood volume (rCBV) derived from dynamic susceptibility contrast (DSC) MRI are predictive of overall survival (OS) in patients...